BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLRX BioLine Rx

Closed 04-30 16:00:00 EDT

2.75

-0.32

-10.42%

盘后2.90

+0.15+5.45%

19:40 EDT

High3.09	Low2.61	Vol77.18K
Open3.09	D1 Closing3.07	Amplitude15.74%
Mkt Cap11.97M	Tradable Cap11.48M	Total Shares4.35M
T/O220.30K	T/O Rate1.85%	Tradable Shares4.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLRX","market":"US","secType":"STK","nameCN":"BioLine Rx","latestPrice":2.75,"timestamp":1777579200000,"preClose":3.07,"halted":0,"volume":77184,"hourTrading":{"tag":"盘后","latestPrice":2.9,"preClose":2.75,"latestTime":"19:40 EDT","volume":686,"amount":1961.39,"timestamp":1777592416665,"change":0.15,"changeRate":0.054545,"amplitude":0.054545},"delay":0,"changeRate":-0.10423452768729637,"floatShares":4173500,"shares":4351357,"eps":-0.286,"marketStatus":"Closed","change":-0.32,"latestTime":"04-30 16:00:00 EDT","open":3.09,"high":3.0932,"low":2.6101,"amount":220298.06338560002,"amplitude":0.157362,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.286,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777622400000},"marketStatusCode":5,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":3.07,"preHourTrading":{"tag":"盘前","latestPrice":3.07,"preClose":3.07,"latestTime":"08:43 EDT","volume":1243,"amount":3848.0422343,"timestamp":1777553039253,"change":0,"changeRate":0,"amplitude":0.045603},"postHourTrading":{"tag":"盘后","latestPrice":2.9,"preClose":2.75,"latestTime":"19:40 EDT","volume":686,"amount":1961.39,"timestamp":1777592416665,"change":0.15,"changeRate":0.054545,"amplitude":0.054545},"volumeRatio":1.888515,"impliedVol":3.7106,"impliedVolPercentile":0.6135},"requestUrl":"/m/hq/s/BLRX/tweets","defaultTab":"tweets","newsList":[{"id":"2621306705","title":"BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306705","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306705?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:06","pubTimestamp":1774357604,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent.  The company reported quarterly sales of $194.000 thousand which missed the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51430236/bioline-rx-q4-epads-0-34-beats-0-54-estimate-sales-194-000k-miss-651-598k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770568","title":"BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770568","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770568?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:16","pubTimestamp":1774264582,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent.  This is a 98.35 percent decrease over sales of $11.749 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51401341/bioline-rx-q4-sales-194-000k-miss-651-598k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621772207","title":"Press Release: BioLineRx Reports 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2621772207","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621772207?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma  by end of this month -. - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -. - Management to host conference call today, March 23, at 8:30 am EDT -. TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BLRX","BK4139","LU2463526074.USD","LU1093756168.USD","ASH","BK4548","LU1721428933.USD","LU2211817866.USD","LU1093756325.SGD","IE00B5TLWC47.USD","LU2413666426.HKD","PFS","LU0347712357.USD","BK4195","IE00BFXG0V08.USD","SCD","IE00BYQQ9H92.USD","BK4588","BK4121","BK4585","BK4533","BK4109","MTD","LU2413666699.HKD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739374","title":"BioLine RX Ltd  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739374","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739374?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:02","pubTimestamp":1774011739,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of77cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results on March 23 for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N408197:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620478831","title":"Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478831","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620478831?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:45","pubTimestamp":1773989100,"startTime":"0","endTime":"0","summary":"BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/20/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/20/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372528/top-wall-street-forecasters-revamp-biolinerx-expectations-ahead-of-q4-earnings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372528/top-wall-street-forecasters-revamp-biolinerx-expectations-ahead-of-q4-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422172","title":"BioLine RX Ltd  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422172","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422172?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:43","pubTimestamp":1773751400,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of77cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results  for the period en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL8N40514T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586141372","title":"BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2586141372","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586141372?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:36","pubTimestamp":1764023799,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49046801/bioline-rx-q3-epads-0-22-beats-1-20-estimate-sales-427-000k-miss-990-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586842497","title":"Analysts Are Bullish on Top Healthcare Stocks: Bioline RX Ltd Sponsored ADR (BLRX), Ocular Therapeutix (OCUL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586842497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586842497?lang=en_us&edition=fundamental","pubTime":"2025-11-25 04:00","pubTimestamp":1764014448,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX – Research Report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-bioline-rx-ltd-sponsored-adr-blrx-ocular-therapeutix-ocul-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-bioline-rx-ltd-sponsored-adr-blrx-ocular-therapeutix-ocul-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4585","BK4112","BK4137","BK4581","XBI","XLV","BLRX","BK4139","BK4007","OCUL","BK4588","LABU","LU0128526141.USD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585746149","title":"Israeli biopharma BioLineRx's Q3 loss narrows as costs drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746149?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:17","pubTimestamp":1763986641,"startTime":"0","endTime":"0","summary":"Israeli biopharma BioLineRx's Q3 loss narrows as costs dropOverviewBioLineRx reports Q3 net loss of $1 mln, narrower than $5.8 mln loss in year-ago quarterCompany says joint venture plan with Hemisphe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL1N3X00A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585658461","title":"Press Release: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2585658461","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585658461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -. - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 -. - Management to host conference call today, November 24 , at 8:30 am EST -. TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.\"At the same time, the ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer, which is being led by Columbia University and supported by both Regeneron and BioLineRx, continues to progress, giving us a second opportunity to leverage our drug development expertise to bring true innovation to patients with difficult-to-treat cancers,\" Mr. Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64QTZ34.USD","PB","BK4109","LU2463526074.USD","MTD","LU2211817866.USD","BK4588","IE00BYQQ9H92.USD","LU1093756168.USD","LU2413666699.HKD","LU0347712357.USD","BK4211","LU1721428933.USD","PFS","BK4139","IE00BLDYK493.USD","BLRX","ASH","BK4195","BK4567","SCD","BK4121","BK4548","LU2413666426.HKD","BK4533","LU1093756325.SGD","IE00BFXG0V08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585657894","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2585657894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585657894?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:00","pubTimestamp":1763982000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Blue Bird Corp                                  4Q      1.05   3:01 PM. ·Cntrl Gdn & Pet                                 4Q      (.20)      AMC. ·Anavex Life Scncs                               4Q      (.15)  7:30 AM. ·Best Buy Co. Inc.                                3Q      1.31       BMO. ·Dick's Sprting Gds                               3Q      2.69   7:00 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLP","CAAP","PFLT","NTNX","CENT","BABA","ZM","EMBC","HPQ","A","ZS","DKS","SMTC","BURL","SYM","DELL","HAFN","LI","CRDO","ARWR","GGAL","NTAP","CLSK","MDB","KEYS","DE","KR","BLBD","PD","SJM","BBY","BLRX","ATAT","GCO","CENTA","CLFD","NAT","AMBA","AVXL","ANF","ADI","BBW","KSS","NIO","ADSK","AMTM","BBAR","DOOO","FLNC","CMBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584338941","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584338941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584338941?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:00","pubTimestamp":1763636400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Jacobs Solutions Inc.                              4Q      1.68   6:45 AM. ·ZIM Integrated Shpg                              3Q       .77   7:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADSK","GGAL","ZM","ZS","A","DRTS","FRO","AZTA","ATKR","ADI","AUNA","WMT","CLCO","BBWI","BULL","CPRT","ATAT","ARWR","AMTM","DKS","DLTR","ANF","FIVE","NTES","AMBA","DELL","BLRX","BBW","BBAR","BBY","CENTA","DOOO","VIPS","ALLT","ESTC","CMBT","CENT","DE","CAL","BLBD","CLFD","CDLR","BJ","FLNC","GAP","MOG.B","BURL","EMBC"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biolinerx.com","stockEarnings":[{"period":"1week","weight":0.3705},{"period":"1month","weight":0.3644},{"period":"3month","weight":-0.0315},{"period":"6month","weight":-0.1153},{"period":"1year","weight":-0.0466},{"period":"ytd","weight":0.1083}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.072241},{"month":2,"riseRate":0.4,"avgChangeRate":-0.047168},{"month":3,"riseRate":0.2,"avgChangeRate":-0.102622},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0071},{"month":5,"riseRate":0.571429,"avgChangeRate":0.094079},{"month":6,"riseRate":0.357143,"avgChangeRate":-0.031443},{"month":7,"riseRate":0.5,"avgChangeRate":0.025637},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055209},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015821},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.018467},{"month":11,"riseRate":0.266667,"avgChangeRate":-0.053503},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.069939}],"exchange":"NASDAQ","name":"BioLine Rx","nameEN":"BioLine Rx","securityTypeName":"DR","adrRate":"1:600"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioLine Rx,BLRX,BioLine Rx股票,BioLine Rx股票老虎,BioLine Rx股票老虎国际,BioLine Rx行情,BioLine Rx股票行情,BioLine Rx股价,BioLine Rx股市,BioLine Rx股票价格,BioLine Rx股票交易,BioLine Rx股票购买,BioLine Rx股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction